DiaSorin (DIA) Investor presentation summary

Market positioning and business overview

• Recognized as a world leader in diagnostics with a unique B2B offering in life sciences, listed on the Italian Stock Exchange and included in the FTSE MIB Index.

• Operates in three main segments: immunodiagnostics (~65% of revenues), molecular diagnostics (~20%), and licensed technologies (~15%), with 2024 revenues guided at approximately €1.2 billion.

• Maintains a global presence with direct operations in all major IVD markets, 35 companies, 10 production facilities, 9 R&D centers, and about 3,200 employees worldwide.

• North America generates about 50% of revenues, Europe 35%, and the rest of the world 15%.

Product and innovation highlights

• Offers a broad immunoassay menu with over 80 specialties and high-volume routine tests, serving hospitals and private labs.

• Launching new algorithm-based diagnostics such as MeMed BV (bacterial vs. viral), Calprotectin 3.0 (IBD/IBS differentiation), and LymeDetect for acute Lyme disease.

• QuantiFERON TB test is positioned as the gold standard for latent tuberculosis, with significant market conversion potential.

• Molecular diagnostics portfolio includes LIAISON PLEX, a flexible, scalable platform with FDA-cleared and pending assays for respiratory, blood culture, and gastrointestinal testing.

Licensed technologies and partnerships

• Licensed technologies segment generates revenue from beads, instruments, and royalties, supporting diagnostics, life science, and biopharma research.

• Partners with leading companies to enable IVD and RUO test development, with applications in transplant, oncology, infectious disease, and biopharma.